TYK Medicines (HKG: 2410) announced that Qilu Pharmaceutical will no longer subscribe for 63,222,744 H shares of the company – terminating the equity leg of their July strategic partnership while leaving the licensing and cooperation agreement for TY‑9591 in full effect.
Deal Snapshot
| Item | Detail |
|---|---|
| Parties | TYK Medicines (HKG: 2410) / Qilu Pharmaceutical |
| Original Agreement Date | 21 Jul 2026 |
| Terminated Component | RMB 400 million H‑share subscription (63,222,744 H shares) |
| Termination Announcement | 29 Sep 2026 |
| Surviving Components | Licensing cooperation agreement + supply and commercialization agreement for TY‑9591 – remain effective |
| Current Market Capitalization | Approximately HKD 1.3 billion (HKEX) |
Restructured Partnership – What Stands and What Falls
- Equity Investment Withdrawn: The RMB 400 million H‑share subscription – intended to establish a deep strategic partnership through equity alignment – has been terminated, with Qilu no longer taking a shareholder position in TYK Medicines.
- TY‑9591 Collaboration Preserved: The licensing and cooperation agreement for TY‑9591 remains effective, covering joint development and production of the active pharmaceutical ingredient (API) of TY‑9591.
- China Commercialization Intact: Qilu Pharmaceutical retains its role in the commercialization of TY‑9591 in Mainland China under the supply and commercialization agreement.
- Asset Profile: TY‑9591’s therapeutic area and clinical stage – not disclosed in the announcement.
Market Impact & Outlook
- Decoupled Structure: The restructuring converts an equity‑plus‑licensing alliance into a pure commercial partnership, giving Qilu access to TY‑9591’s China rights without balance‑sheet exposure to TYK’s equity.
- Financing Gap for TYK: Losing the RMB 400 million subscription removes a committed capital injection; with market capitalization at roughly HKD 1.3 billion, alternative financing paths – placement, partnerships, or debt – become a focus for investors. Terms of any replacement funding – not disclosed.
- Signal on Deal Confidence: The survival of the API development and commercialization agreements indicates continued commercial conviction in TY‑9591 despite the equity withdrawal.
- Termination Rationale: Reasons for Qilu’s decision to exit the share subscription – not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding partnership execution, asset development, commercialization plans, and financing prospects for TYK Medicines and its collaboration with Qilu Pharmaceutical. Actual results may differ due to risks including regulatory outcomes for TY‑9591, API development and supply execution, market adoption in Mainland China, capital‑raising conditions, and equity market volatility affecting the company’s HKD 1.3 billion market capitalization.-Fineline Info & Tech
